Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.06 +1.23%

+$0.04 today

Market cap
$227.58M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 4.13M

Average 3.33M

CABA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Cabaletta Bio, Inc.NASDAQ: CABA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $43.52M (cash outflow) rose 21.1% year over year, behind the +38.4% change in trailing-twelve-month net income. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at +46.9% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$133.66M (-20.4%) for the fiscal year ending Dec 2026, a slowdown from the +44.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$43.52M+3.8% QoQ
Last fiscal yearDec 2025
-$167.86M+44.9% YoY
LTMMar 2026
-$175.43M+38.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.1%-7.4%-28.5 pp
1 year+44.9%-20.4%-65.2 pp
3-year CAGR+46.9%+12.7%-34.2 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(167.86M) USD
Year-over-year change
-44.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CABA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +38.4% is the 4th highest of 11, against a peer median of +14.5%.
  • Over three fiscal years its annual growth of +46.9% compares with a peer median of +16.7%.
CABA Competitors
Net Income for CABA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$80.71B USD+146477.0%+53.5%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$246.41M USD-26.3%+14.4%794858.1%
CABACabaletta Bio, Inc.LTM Mar 2026$175.43M USD+38.4%+46.9%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$173.76M USD-31.1%-16.9%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$169.52M USD+21.5%+11.0%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$156.4M USD+7.6%+77.4%—
EDITEditas Medicine, Inc.LTM Mar 2026$108.95M USD-56.6%-10.1%281.6%
HUMAHumacyte, Inc.LTM Mar 2026$97.59M USD+25.7%+50.6%4840.8%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$87.5M USD-19.9%+19.0%—
IMMPImmutep LimitedFY2025A$61.43M AUD+43.8%+24.0%1218.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026€45.62M EUR+51.2%-14.2%339.4%
Peer median (excluding CABA) —+14.5%+16.7%1218.0%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Depreciation & Amortization733K1.18M1.43M1.71M1.65M
Deferred Income Tax00000
Stock-Based Compensation5.8M6.9M11.34M19.47M20.94M
Change in Working Capital5.58M(4.3M)101K1.61M(379K)
Accounts Receivables00000
Inventory00000
Accounts Payables975K(28K)1.68M1.01M1.55M
Other Working Capital4.61M(4.27M)(1.57M)600K(1.93M)
Other Non-Cash Items62K2.82M1.26M4.86M14.57M
Operating Cash Flow(34.11M)(46.38M)(53.55M)(88.22M)(131.08M)
Capital Expenditures(1.17M)(2.45M)(687K)(2.21M)(1.23M)
Acquisitions (Net)024.76K000
Purchases of Investments0(49.76M)(84.26M)0(99.04M)
Sales of Investments7.17M25M62.5M49.5M50M
Other Investing Activities0(24.76K)000
Investing Cash Flow6M(27.22M)(22.45M)47.29M(50.27M)
Debt Repayment000(897K)(6.26M)
Common Stock Issued48.25M32.86M185.2M10.88M106.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities650K127K2.43M1.7M0
Financing Cash Flow48.9M32.98M187.63M11.68M100.35M
Effect of Forex Changes000(20K)19K
Net Change in Cash20.79M(40.62M)111.63M(29.28M)(80.98M)
Free Cash Flow(35.28M)(48.83M)(54.24M)(90.43M)(132.31M)

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.